HIV Genomic Aging Project in Oncology (HIV-GAP)

肿瘤学中的 HIV 基因组衰老项目 (HIV-GAP)

• 批准号: 10403025
• 负责人: Anna Coghill
• 金额: $ 77.86万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10403025
• 关键词: AIDS related cancer; Accounting; Address; Age; Aging; Biological; Biological Aging; Biological Markers; Blood; Blood Cells; Cancer Burden; Cancer Center; Cancer Patient; Cancer Relapse; Cardiovascular Diseases; Cause of Death; Cessation of life; Chronic Disease; Chronology; Clinical; Clinical Management; Consent; DNA; DNA Methylation; Data; Development; Diagnosis; Disease; Ensure; Epigenetic Process; Evaluation; Evolution; Female; Future; Gait speed; Gastrointestinal Neoplasms; Gender; General Population; Genomics; Goals; Gynecologic; Gynecologic Oncology; HIV; HIV Seronegativity; Hematopoiesis; Hematopoietic stem cells; Immune System Diseases; Incidence; Individual; Inferior; Inflammation; Institutes; Institution; Investigation; Knowledge; Lead; Life Expectancy; Link; Malignant Neoplasms; Measures; Modification; Monitor; Mutation; Neoplasm Metastasis; Oncology; Outcome; Patients; Persons; Prevalence; Process; Prognosis; Protocols documentation; Race; Recurrent disease; Refractory; Risk Factors; Role; Sample Size; Sampling; Selection for Treatments; Site; Solid Neoplasm; Time; Translating; Tumor Tissue; Vital Status; Work; adverse outcome; age group; age related; anti aging; antiretroviral therapy; base; bead chip; cancer complication; cancer diagnosis; cancer therapy; cohort; experience; follow-up; functional status; gastrointestinal; genomic biomarker; improved; instrumental activity of daily living; male; men; mortality; mortality risk; next generation sequencing; novel; novel strategies; programs; prospective; sample collection; tool; translational impact; tumor

ABSTRACT. People with HIV (PWH) experience higher cancer mortality and increased likelihood of cancer relapse after initial therapy compared to HIV-uninfected cancer patients. Our prior work demonstrated that these HIV-associated cancer outcome disparities persist after accounting for known risk factors. A novel approach to identify targetable drivers of the poor cancer outcomes experienced by PWH is urgently needed to improve prognosis. We posit that cancer outcomes in PWH are negatively impacted by prolonged immune dysfunction that results in accelerated biological aging. Biological aging can be quantified using genomic biomarkers, such as DNA methylation translated into epigenetic clocks and presence of age-related clonal hematopoiesis (ARCH). The overarching goal of this proposal is to compare biological age, measured using genomic biomarkers, between cancer patients with versus without HIV and to quantify associations between measured biological age with important clinical outcomes. Previous studies in PWH (without cancer) indicate that HIV-infected individuals have higher biological age, calculated using blood-based epigenetic clocks, compared to their chronological age. This accelerated aging was associated with increased mortality. ARCH has also been reportedly increased in PWH. ARCH is characterized by acquired mutations that expand over time in blood cells. Accumulation of these mutations is linked to increased inflammation and adverse outcomes. Data suggest that ARCH may be twice as prevalent in PWH (without cancer) compared to HIV-uninfected persons. Thus, there is evidence for a link between HIV and advanced genomic aging in PWH (without cancer), which warrants exploration in the context of cancer. To preliminarily explore our hypothesis, we sequenced blood DNA from 30 solid tumor patients (15 PWH and 15 HIV-uninfected) matched on chronological age. Our preliminary data indicate that genomic aging is more advanced in cancer patients with HIV. We observed significantly higher epigenetic-based biological age in the PWH. We detected ARCH mutations in 3 PWH but 0 HIV-uninfected patients. The median survival in PWH was only 2 years, compared to 9 years in HIV-uninfected patients; most striking was the <1-year median survival in the PWH with ARCH. In this proposal, we will utilize an established protocol at Moffitt Cancer Center and Huntsman Cancer Institute to prospectively collect biospecimens from 400 cancer patients (200 with and 200 without HIV). The investigation is timely and compelling given that cancer is now a leading cause of death in PWH, and incidence is increasing. We propose the following aims: 1) Compare the biological age of cancer patients with versus without HIV using epigenetic clocks; 2) Compare baseline prevalence and therapy-related evolution of ARCH between cancer patients with and without HIV; and 3) Quantify the association between genomic biomarkers of aging and clinical outcomes, including aging-related functional assessments. This study will address the critical knowledge gap of whether cancer patients with HIV are biologically older than age- matched cancer patients without HIV, and whether this advanced aging contributes to poor cancer outcomes.

摘要。艾滋病毒感染者（PWH）的癌症死亡率更高，患癌症的可能性也更高